Antiangiogenic therapy in the management of brain tumors: a clinical overview

Area of Science:

• Neuro-oncology
• Cancer Biology
• Molecular Medicine

Background:

• Angiogenesis is critical for brain tumor development, involving numerous molecular targets.
• Antiangiogenic therapies have emerged as a treatment strategy for brain tumors.
• Current therapies include inhibitors of vascular endothelial growth factor, platelet-derived growth factor, integrins, and histone deacetylase.

Purpose of the Study:

• To review the development and effectiveness of antiangiogenic therapies for brain tumors.
• To discuss the challenges posed by tumor escape mechanisms.
• To highlight the need for novel therapeutic strategies.

Main Methods:

• Literature review of antiangiogenic agents and their mechanisms of action.
• Analysis of clinical trial data on the efficacy and toxicity of these therapies.
• Examination of known tumor resistance pathways.

Main Results:

• Several antiangiogenic agents demonstrate efficacy with manageable toxicity.
• Tumors can develop resistance through various escape mechanisms.
• Combination therapies and multi-targeted agents show potential in preclinical studies.

Conclusions:

• Antiangiogenic therapies are a valuable addition to brain tumor treatment.
• Overcoming therapeutic resistance is a key challenge.
• Further research into multi-targeted agents is essential for improved patient outcomes.